Mogamulizumab to Prevent Leukemia in HTLV-1 Carriers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a drug called mogamulizumab can prevent adult T-cell leukemia/lymphoma in people who carry the HTLV-1 virus and have a high viral load. It is for patients who have not yet developed the blood cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must test positive for HTLV-1 (a virus that can lead to this leukemia) with a high viral load (≥8% in your white blood cells).
- You are at least 18 years old and have given written consent.
- Your blood counts and liver, kidney, and lung function must be within safe limits (doctors will check this).
- You cannot have had certain other cancers or autoimmune diseases in the recent past.
- You must not have serious uncontrolled health issues like heart failure or active tuberculosis.
- If you are of childbearing age, you must use effective contraception during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
This trial tests a new drug called OJP-001 for people with adult T-cell leukemia/lymphoma (ATL) that has come back or not responded to other treatments. The goal is to see if this drug can help control the disease.
This study tracks safety in adults who had a stem cell transplant after taking mogamulizumab. It looks at outcomes and side effects over time, helping doctors understand risks for future patients.
This trial tests a T-cell therapy for people with PML, a rare brain infection. It aims to boost your immune system to fight the virus causing PML. You may be eligible if you have PML not caused by HIV, natalizumab, or certain recent treatments.
Hear when a new T-cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.